Sunzen Biotech Berhad (KLSE:SUNZEN) commences share repurchases on September 20, 2022, under the program mandated by the shareholders in the Annual General Meeting held on June 22, 2022. As per the mandate, the company is authorized to repurchase up to 10% of its issued share capital, such that the company's holding in treasury together with the shares repurchased does not exceed 10% of its issued share capital. The repurchases will be funded from the internally generated funds of the company and/or borrowings.

The shares repurchased will be cancelled or retained as treasury shares where such shares may be distributed as share dividends to the shareholders or transfer the treasury shares for purposes of or under an employees' share scheme or transfer the shares as purchase consideration. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual general Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting.